CCR2 and melanoma: Etzerodt et al. developed an anti-CD163 IgG mAb conjugated with lipid nanoparticles loaded with the cytotoxic agent doxorubicin.109 In a mouse model of BRAF-mutant melanoma, the group demonstrated that the antibody was able to deplete CD163+ TAMs and this depletion led to an almost complete inhibition of tumor growth, which was more effective than pan-TAM blockade using CSF1R and CCR2 inhibition.